Overview

Nonalcoholic fatty liver disease is an umbrella term for a range of liver conditions affecting people who drink little to no alcohol. As the name implies, the main characteristic of nonalcoholic fatty liver disease is too much fat stored in liver cells.

Nonalcoholic steatohepatitis, a potentially serious form of the disease, is marked by liver inflammation, which may progress to scarring and irreversible damage. This damage is similar to the damage caused by heavy alcohol use. At its most severe, nonalcoholic steatohepatitis can progress to cirrhosis and liver failure

Nonalcoholic fatty liver disease is increasingly common around the world, especially in Western nations. In the United States, it is the most common form of chronic liver disease, affecting an estimated 80 to 100 million people.

Nonalcoholic fatty liver disease occurs in every age group but especially in people in their 40s and 50s who are at high risk of heart disease because of such risk factors as obesity and type 2 diabetes. The condition is also closely linked to metabolic syndrome, which is a cluster of abnormalities including increased abdominal fat, poor ability to use the hormone insulin, high blood pressure and high blood levels of triglycerides, a type of fat.

Nonalcoholic fatty liver disease care at Mayo Clinic

Symptoms

Nonalcoholic fatty liver disease usually causes no signs and symptoms. When it does, they may include:

  • Enlarged liver
  • Fatigue
  • Pain in the upper right abdomen

Possible signs and symptoms of nonalcoholic steatohepatitis and cirrhosis (advanced scarring) include:

  • Abdominal swelling (ascites)
  • Enlarged blood vessels just beneath the skin's surface
  • Enlarged breasts in men
  • Enlarged spleen
  • Red palms
  • Yellowing of the skin and eyes (jaundice)

When to see a doctor

Make an appointment with your doctor if you have persistent signs and symptoms that cause you concern.

Causes

Experts don't know exactly why some people accumulate fat in the liver while others do not. Similarly, there is limited understanding of why some fatty livers develop inflammation that progresses to cirrhosis. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis are both linked to the following:

  • Overweight or obesity
  • Insulin resistance, in which your cells don't take up sugar in response to the hormone insulin
  • High blood sugar (hyperglycemia), indicating prediabetes or actual type 2 diabetes
  • High levels of fats, particularly triglycerides, in the blood

These combined health problems appear to promote the deposit of fat in the liver. For some people, this excess fat acts as a toxin to liver cells, causing liver inflammation and nonalcoholic steatohepatitis, which may lead to a buildup of scar tissue (fibrosis) in the liver.

Risk factors

A wide range of diseases and conditions can increase your risk of nonalcoholic fatty liver disease, including:

  • High cholesterol
  • High levels of triglycerides in the blood
  • Metabolic syndrome
  • Obesity, particularly when fat is concentrated in the abdomen
  • Polycystic ovary syndrome
  • Sleep apnea
  • Type 2 diabetes
  • Underactive thyroid (hypothyroidism)
  • Underactive pituitary gland (hypopituitarism)

Nonalcoholic steatohepatitis is more likely in these groups:

  • Older people
  • People with diabetes
  • People with body fat concentrated in the abdomen

It is difficult to distinguish nonalcoholic fatty liver disease from nonalcoholic steatohepatitis without further testing.

Complications

The main complication of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis is cirrhosis, which is late-stage scarring (fibrosis) in the liver. Cirrhosis occurs in response to liver injury, such as the inflammation in nonalcoholic steatohepatitis.  As the liver tries to halt inflammation, it produces areas of scarring (fibrosis). With continued inflammation, fibrosis spreads to take up more and more liver tissue.

If the process isn't interrupted, cirrhosis can lead to:

  • Fluid buildup in the abdomen (ascites)
  • Swelling of veins in your esophagus (esophageal varices), which can rupture and bleed
  • Confusion, drowsiness and slurred speech (hepatic encephalopathy)
  • Liver cancer
  • End-stage liver failure, which means the liver has stopped functioning

About 20 percent of people with nonalcoholic steatohepatitis will progress to cirrhosis.

Prevention

To reduce your risk of nonalcoholic fatty liver disease:

  • Choose a healthy diet. Choose a healthy plant-based diet that's rich in fruits, vegetables, whole grains and healthy fats.
  • Maintain a healthy weight. If you are overweight or obese, reduce the number of calories you eat each day and get more exercise. If you have a healthy weight, work to maintain it by choosing a healthy diet and exercising.
  • Exercise. Exercise most days of the week. Get an OK from your doctor first if you haven't been exercising regularly.

Nonalcoholic fatty liver disease care at Mayo Clinic

Aug. 11, 2017
References
  1. Chalasani N, et al. The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases and American College of Gastroenterology. Gastroenterology. 2012;142:1592.
  2. Feldman M, et al. Nonalcoholic fatty liver disease. In: Sleisenger & Fordtran's Gastrointestinal and Liver Disease: Pathophysiology, Diagnosis, Management. 10th ed. Philadelphia, Pa.: Saunders Elsevier; 2016. http://www.clinicalkey.com. Accessed May 10, 2016.
  3. Rinella M. Nonalcoholic fatty liver disease: A systematic review. Journal of the American Medical Association. 2015;313:2263. http://jama.jamanetwork.com/ Accessed May 10, 2016.
  4. Spengler E, et al. Recommendations for diagnosis, referral for liver biopsy, and treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. http://www.mayoclinicproceedings.org/article/S0025-6196(15)00510-8/abstract. Mayo Clinic Proceedings. 2015;90:1233. Accessed May 10, 2015.
  5. Barbara Woodward Lips Patient Education Center. Nonalcoholic fatty liver disease. Rochester, Minn.: Mayo Foundation for Medical Education and Research; 2009.
  6. Venkatesh SK, et al. Magnetic resonance elastography of liver: Technique, analysis and clinical applications. Journal of Magnetic Resonance Imaging. 2013;37:544.
  7. Kim D, et al. Advanced fibrosis in nonalcoholic fatty liver disease: Noninvasive assessment with MR elastography. Radiology. 2013;268:411.
  8. Sheth SG, et al. Nonalcoholic fatty liver disease: Natural history and management. http://www.uptodate.com/home. Accessed May 10, 2016.
  9. Boyer TD, et al. Nonalcoholic fatty liver disease. In: Zakim & Boyer's Hepatology: A Textbook of Liver Disease. 6th ed. Philadelphia, Pa: Saunders Elsevier, 2012. http://www.clinicalkey.com. Accessed May 10, 2015.
  10. Molloy JW, et al. Association of coffee and caffeine consumption with fatty liver disease, nonalcoholic steatohepatitis and degree of hepatic fibrosis. Hepatology. 2012;55:429.
  11. Malhi H, et al. Nonalcoholic fatty liver: Optimizing pretransplant selection and posttransplant care to maximize survival. Current Opinion in Organ Transplantation. 2016, 21:99.
  12. Heimbach J, et al. Combined liver transplantation and gastric sleeve resection for patients with medically complicated obesity and end-stage liver disease. American Journal of Transplantation. 2013; 13:363.
  13. Watt KD (expert opinion). Mayo Clinic, Rochester, Minn. Personal communication. July 7, 2016.
  14. Ludwig J, et al. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clinic Proceedings. 1980;55:434.
  15. Uppal V, et al. Pediatric non-alcoholic fatty liver disease. Current Gastroenterology Reports. 2016;18:24.